Genflow Biosciences annual shareholders’ equity
2021
2022
2023
2024
2025
Genflow Biosciences Shareholders’ Equity Growth & History (GENF)
Genflow Biosciences's shareholders’ equity was −£550,785 for fiscal 2025.
View full Genflow Biosciences company overviewGenflow Biosciences annual shareholders’ equity history
| Fiscal year | Period ended | Shareholders’ equity | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −£550,785 | −£147,777 | — |
| 2024 | 2024-12-31 | −£403,008 | −£902,701 | — |
| 2023 | 2023-12-31 | £499,693 | −£1.9M | −78.88% |
| 2022 | 2022-12-31 | £2.4M | £2.3M | +4193.00% |
| 2021 | 2021-12-31 | £55,124 | — | — |
Genflow Biosciences quarterly shareholders’ equity
Q4.24
Q2.25
Q4.25
| Fiscal quarter | Period ended | Shareholders’ equity | Change | YoY change |
|---|---|---|---|---|
| Q4 2025 | 2025-12-31 | −£550,785 | −£147,777 | — |
| Q2 2025 | 2025-06-30 | −£303,003 | — | — |
| Q4 2024 | 2024-12-31 | −£403,008 | — | — |
Genflow Biosciences shareholders’ equity trends
Between the periods ended 2021-12-31 and 2025-12-31, Genflow Biosciences's shareholders’ equity decreased from £55,124 to −£550,785, a change of −£605,909. The latest reported quarter, Q4 2025, shows −£550,785.
About the metric
What shareholders’ equity means
Shareholders’ equity is the residual accounting value attributable to shareholders after liabilities are subtracted from assets. It can change through earnings, losses, dividends, share issuance, repurchases, and other comprehensive income.
Calculation and source
reported shareholders’ equity
TickerStat standardizes stockholders’ or shareholders’ equity reported in company official filings at each balance-sheet date. Negative equity is retained because it can be economically meaningful. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Genflow Biosciences source filings ↗